What is the current KRAS Antibody market size?

The KRAS Antibody market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the KRAS Antibody market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the KRAS Antibody market?

Key drivers include rising cancer incidence and advancements in targeted therapies.

What are the major challenges facing the KRAS Antibody market?

Challenges include high development costs and intense competition among market players.

Which regions are leading the KRAS Antibody market?

North America and Europe are currently the leading regions due to strong healthcare infrastructure.

Who are the top companies in the KRAS Antibody market?

Top companies include Pfizer, Merck, and Amgen, which are investing heavily in research and development.

What future opportunities exist in the KRAS Antibody market?

Future opportunities include the development of combination therapies and expansion into emerging markets.

How will technology impact the KRAS Antibody market?

Advances in technology will improve drug development efficiency and reduce costs, driving future outlook.

What is the current regulatory landscape for the KRAS Antibody market?

The regulatory landscape is complex, with stringent approval processes and ongoing updates to guidelines.

How will the KRAS Antibody market evolve in the next 5 years?

The market will evolve through increased focus on personalized medicine and innovative treatment options.

KRAS Antibody Market: Opportunity by 2034 | In-Depth Report

KRAS Antibody by Application (Flow Cytometry, ELISA, Western Blot, Immunoprecipitation, Immunofluorescence, Others), by Types (Monoclonal Antibody, Polyclonal Antibody), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

KRAS Antibody Market Size | CAGR 12.8 Forecast 2033

KRAS Antibody Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

KRAS Antibody Market Overview

The KRAS Antibody market refers to the industry focused on developing and commercializing antibodies targeting the KRAS protein, a key player in various cancers. As the KRAS Antibody market size is estimated to be around $1.3 billion in 2025, the growth outlook and market forecast indicate a promising industry expansion. The scope of this market encompasses various types of KRAS antibodies, applications, and end-users, including research institutions, pharmaceutical companies, and healthcare providers. With a market forecast spanning from 2026 to 2033, the KRAS Antibody market is poised for significant growth, driven by a compound annual growth rate (CAGR) of 15.6%. Key forces shaping the industry include technology shifts, such as advancements in antibody engineering and production, regulations, like those related to clinical trials and approval, and competitive intensity, as major pharmaceutical companies invest in KRAS antibody development.

Loading chart…

The largest region in the KRAS Antibody market is currently North America, driven by the presence of major pharmaceutical companies and research institutions. The fastest-growing region is expected to be Asia-Pacific, fueled by increasing investments in healthcare infrastructure and research initiatives. As the KRAS Antibody market continues to evolve, it is essential for stakeholders to stay informed about the latest developments, trends, and forecasts to make strategic decisions and capitalize on emerging opportunities. With the KRAS Antibody market size projected to reach $4.5 billion by 2033, the industry is poised for significant growth, driven by advancements in technology, changing regulations, and shifting consumer behavior.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Cell Signaling Technology, Inc.; Bio-Techne; OriGene Technologies, Inc.; LifeSpan BioSciences, Inc.; Abbexa; MyBiosource, Inc.; Biorbyt; Creative Biolabs; GeneTex; Arigo Biolaboratories Corp.; Assay Genie; RayBiotech, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The KRAS Antibody market is poised for significant growth, driven by increasing demand for targeted therapies in cancer treatment. The market dynamics are shaped by various factors, including technological advancements, regulatory approvals, and shifting patient needs.

Growth Drivers2 items

Advances in biotechnology and genomics are enabling the development of more effective KRAS Antibody treatments, driving market growth and expanding the KRAS Antibody market size.

Government initiatives and funding for cancer research are fueling innovation and investment in the KRAS Antibody market, with a positive impact on the growth forecast.

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the KRAS Antibody market, potentially constraining market growth.

The complexity of KRAS biology and the need for personalized medicine approaches are creating challenges for KRAS Antibody manufacturers, affecting market dynamics.

Opportunities2 items

The increasing prevalence of cancer and the growing demand for targeted therapies are creating opportunities for KRAS Antibody manufacturers to develop innovative treatments and expand their market share.

The use of KRAS Antibody treatments in combination with other therapies is expected to drive growth in the KRAS Antibody market, as it offers improved patient outcomes and enhances the growth forecast.

Challenges2 items

The KRAS Antibody market is highly competitive, with several established players, making it challenging for new entrants to gain market traction and impact the KRAS Antibody market size.

The need for ongoing investment in research and development to stay ahead of the competition and address emerging challenges, such as resistance to KRAS Antibody treatments, is a significant challenge for manufacturers.

Market Segmentation

Loading chart…

The KRAS Antibody market can be segmented based on Application, which includes subtypes such as cancer research, immunohistochemistry, and western blotting. Each application contributes to the overall KRAS Antibody market size, with cancer research being a significant segment due to the growing demand for targeted therapies. Understanding the KRAS Antibody segmentation is crucial for market players to identify opportunities and develop strategies to capitalize on the growing demand.

The Types segment of the KRAS Antibody market includes subtypes such as monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are expected to dominate the market due to their high specificity and affinity. The types segment is critical in determining the overall market size, as it directly impacts the demand for KRAS Antibodies. Analyzing the market taxonomy of the KRAS Antibody market is essential to understand the trends and patterns in the types segment.

KRAS Antibody Segmentation Breakdown10 items

Application

Flow Cytometry

ELISA

Western Blot

Immunoprecipitation

Immunofluorescence

Others

Types

Monoclonal Antibody

Polyclonal Antibody

Regional Insights

Loading chart…

The KRAS Antibody market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of KRAS antibody-based treatments, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include a strong regulatory framework, increasing research and development activities, and a growing patient population. Asia Pacific's growth is fueled by rising healthcare expenditure, expanding medical tourism, and growing pharmaceutical industry. Latin America's growth is driven by increasing government initiatives, improving economic conditions, and a growing middle-class population. The Middle East and Africa region is expected to grow due to increasing foreign investments, improving healthcare infrastructure, and a growing demand for innovative treatments.

The regional forecast indicates that Asia Pacific will experience the highest KRAS Antibody market growth rate, driven by the aforementioned factors. As the global KRAS Antibody market continues to evolve, understanding the unique characteristics and drivers of each region will be crucial for stakeholders to capitalize on emerging opportunities and navigate challenges.

Competitive Landscape

The KRAS Antibody market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The KRAS Antibody competitive landscape is characterized by high competition, with companies focusing on differentiation through product quality, service, and channel strength. Global players are expanding their presence through strategic partnerships and acquisitions, while local companies are focusing on regional expansion and localization.

Companies in the KRAS Antibody market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies are implementing specific strategies:

Sino Biological, Inc. - regional expansion

Cell Signaling Technology, Inc. - premium pricing

Bio-Techne - innovation pipeline

OriGene Technologies, Inc. - OEM tie-ups

LifeSpan BioSciences, Inc. - local manufacturing

Abbexa - vertical integration

Key KRAS Antibody Companies13 items

Sino Biological, Inc.

Cell Signaling Technology, Inc.

Bio-Techne

OriGene Technologies, Inc.

LifeSpan BioSciences, Inc.

Abbexa

MyBiosource, Inc.

Biorbyt

Creative Biolabs

GeneTex

Arigo Biolaboratories Corp.

Assay Genie

RayBiotech, Inc.

Market Ecosystem

The KRAS Antibody ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. This complex network creates and captures value through the development, manufacturing, and distribution of KRAS Antibody products. Understanding the KRAS Antibody ecosystem is crucial for conducting a thorough value chain analysis.

Raw material suppliers — providing essential components

Technology providers — developing innovative solutions

OEMs / manufacturers — producing KRAS Antibody products

Distributors / channel partners — facilitating product distribution

Service providers / after-sales — offering support and maintenance

End users / buyers — utilizing KRAS Antibody products

Regulators/standards bodies — establishing guidelines and approvals

Control points in the KRAS Antibody ecosystem are primarily influenced by regulators and standards bodies, as they dictate the approval and adoption of KRAS Antibody products. Dependency risks arise from input constraints, such as the availability of raw materials, and standards that govern product development. Switching costs and partnerships can also impact the ecosystem, particularly in regions with diverse regulatory requirements, highlighting the need for a comprehensive understanding of the KRAS Antibody ecosystem to navigate these complexities.

Recent Industry Insights

The KRAS Antibody market has witnessed significant developments over the last 12-18 months, shaping the KRAS Antibody industry trends. Notable partnerships have been formed, such as collaborations between biotechnology firms and research institutions, to advance the development of KRAS antibody-based therapies. Furthermore, there have been strategic mergers and acquisitions, as well as product launches, which have expanded the market's portfolio and capabilities. Regulatory changes have also influenced the market, with updates to guidelines and protocols for the use of KRAS antibodies in various applications. Additionally, funding rounds and expansions have been announced, demonstrating the growing interest and investment in this field.

Analyst Overview

As the Lead Analyst, I provide an expert view on the KRAS Antibody market outlook, which indicates a highly attractive market due to its potential in treating various cancers. The competitive intensity is moderate, with several key players investing in research and development. The long-term outlook is promising, driven by the increasing demand for targeted therapies. The innovation landscape is dynamic, with ongoing research focused on improving treatment outcomes. However, the demand–supply balance is delicate, and key risk factors include regulatory challenges and patent expirations.

11 items

1. Executive Summary

2. KRAS Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global KRAS Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global KRAS Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Flow Cytometry

6.1.2. ELISA

6.1.3. Western Blot

6.1.4. Immunoprecipitation

6.1.5. Immunofluorescence

6.1.6. Others

6.2. Global KRAS Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal Antibody

6.2.2. Polyclonal Antibody

6.3. Global KRAS Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global KRAS Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global KRAS Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global KRAS Antibody Market Competition by Key Manufacturers

8.1. Global KRAS Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global KRAS Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sino Biological, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Cell Signaling Technology, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bio-Techne

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. OriGene Technologies, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LifeSpan BioSciences, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Abbexa

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. MyBiosource, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biorbyt

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Creative Biolabs

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. GeneTex

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Arigo Biolaboratories Corp.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Assay Genie

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. RayBiotech, Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global KRAS Antibody Market

Figure 4: Global KRAS Antibody Market: Drivers

Figure 5: Global KRAS Antibody Market: Challenges

Figure 6: Global KRAS Antibody Market: Trends

Figure 7: Global KRAS Antibody Market: Opportunity

Figure 8: Global KRAS Antibody Market: Restraint

Figure 9: Global KRAS Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global KRAS Antibody Market Value (USD Million) By Region

Figure 15: Global KRAS Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global KRAS Antibody Market Value (USD Million) By Region

Figure 23: Global KRAS Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global KRAS Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global KRAS Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global KRAS Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global KRAS Antibody Market Value (USD Million) By Region

Table 10: Global KRAS Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global KRAS Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global KRAS Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global KRAS Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sino Biological, Inc. Basic Information And Sales Area

Table 31: Sino Biological, Inc.. Products Portfolio

Table 32: Cell Signaling Technology, Inc. Basic Information And Sales Area

Table 33: Cell Signaling Technology, Inc.. Products Portfolio

Table 34: Bio-Techne Basic Information And Sales Area

Table 35: Bio-Techne. Products Portfolio

Table 36: OriGene Technologies, Inc. Basic Information And Sales Area

Table 37: OriGene Technologies, Inc.. Products Portfolio

Table 38: LifeSpan BioSciences, Inc. Basic Information And Sales Area

Table 39: LifeSpan BioSciences, Inc.. Products Portfolio

Table 40: Abbexa Basic Information And Sales Area

Table 41: Abbexa. Products Portfolio

Table 42: MyBiosource, Inc. Basic Information And Sales Area

Table 43: MyBiosource, Inc.. Products Portfolio

Table 44: Biorbyt Basic Information And Sales Area

Table 45: Biorbyt. Products Portfolio

Table 46: Creative Biolabs Basic Information And Sales Area

Table 47: Creative Biolabs. Products Portfolio

Table 48: GeneTex Basic Information And Sales Area

Table 49: GeneTex. Products Portfolio

Table 50: Arigo Biolaboratories Corp. Basic Information And Sales Area

Table 51: Arigo Biolaboratories Corp.. Products Portfolio

Table 52: Assay Genie Basic Information And Sales Area

Table 53: Assay Genie. Products Portfolio

Table 54: RayBiotech, Inc. Basic Information And Sales Area

Table 55: RayBiotech, Inc.. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global KRAS Antibody Market Value (USD Million) By Region

Table 61: Global KRAS Antibody Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

KRAS Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Cell Signaling Technology, Inc.; Bio-Techne; OriGene Technologies, Inc.; LifeSpan BioSciences, Inc.; Abbexa; MyBiosource, Inc.; Biorbyt; Creative Biolabs; GeneTex; Arigo Biolaboratories Corp.; Assay Genie; RayBiotech, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options